A tale of two cannabinoids: The therapeutic rationale for combining tetrahydrocannabinol and cannabidiol

Medical Hypotheses

Volumn 66, Issue 2, 2006, Pages 234-246

  Russo, Ethan ^a,b,c,d   Guy, Geoffrey W ^a  

^a Porton Down Science Park   (United Kingdom)

^b UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF MONTANA   (United States)

^d NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANNABIDIOL; CANNABINOID RECEPTOR; CANNABIS; DRONABINOL; PROSTAGLANDIN SYNTHASE INHIBITOR; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG; VANILLOID RECEPTOR;

ANALGESIC ACTIVITY; ANTIEMETIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; BRACHIAL PLEXUS INJURY; CANCER PAIN; CLINICAL EFFECTIVENESS; CLINICAL PROTOCOL; CLINICAL TRIAL; DRUG DEPENDENCE; DRUG MEGADOSE; DRUG SAFETY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; INTOXICATION; MULTIPLE SCLEROSIS; NEOPLASM; NEUROPATHIC PAIN; NEUROPROTECTION; NONHUMAN; PAIN; PARKINSONISM; PRACTICE GUIDELINE; PRIORITY JOURNAL; RATING SCALE; REVIEW; RHEUMATOID ARTHRITIS; SEDATION; SLEEP DISORDER; SPASTICITY; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINARY TRACT INFECTION;

CANNABIS;

EID: 28844489930     PISSN: 03069877     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.mehy.2005.08.026     Document Type: Article

References (117)

1. W.A. Devane, L. Hanus, A. Breuer, R.G. Pertwee, L.A. Stevenson, and G. Griffin Isolation and structure of a brain constituent that binds to the cannabinoid receptor Science 258 5090 1992 1946 1949
2. E. Fride, and R. Mechoulam Pharmacological activity of the cannabinoid receptor agonist, anandamide, a brain constituent Eur J Pharmacol 231 2 1993 313 314
3. R.G. Pertwee Cannabis and cannabinoids: pharmacology and rationale for clinical use Pharm Sci 3 1997 539 545
4. M. Begg, P. Pacher, S. Batkai, D. Osei-Hyiaman, L. Offertaler, and F.M. Mo Evidence for novel cannabinoid receptors Pharmacol Ther 106 2 2005 133 145
5. E.P. de Meijer, M. Bagatta, A. Carboni, P. Crucitti, V.M. Moliterni, and P. Ranalli The inheritance of chemical phenotype in Cannabis sativa L Genetics 163 1 2003 335 346
6. J.M. McPartland, and E.B. Russo Cannabis and cannabis extracts: greater than the sum of their parts? Journal of Cannabis Therapeutics 1 3-4 2001 103 132
7. R. Mechoulam, and S. Ben-Shabat From gan-zi-gun-nu to anandamide and 2-arachidonoylglycerol: the ongoing story of cannabis Nat Prod Rep 16 2 1999 131 143
8. E.A. Carlini, I.G. Karniol, P.F. Renault, and C.R. Schuster Effects of marihuana in laboratory animals and in man Brit J Pharmacol 50 2 1974 299 309
9. J.W. Fairbairn, and J.T. Pickens Activity of cannabis in relation to its delta′-trans-tetrahydro-cannabinol content Brit J Pharmacol 72 3 1981 401 409
10. B.J. Whalley, J.D. Wilkinson, E.M. Williamson, and A. Constanti A novel component of cannabis extract potentiates excitatory synaptic transmission in rat olfactory cortex in vitro Neurosci Lett 365 1 2004 58 63
11. E.B. Russo Hemp for headache: an in-depth historical and scientific review of cannabis in migraine treatment J Cannabis Ther 1 2 2001 21 92
12. S.R. Calhoun, G.P. Galloway, and D.E. Smith Abuse potential of dronabinol (Marinol) J Psychoactive Drugs 30 2 1998 187 196
13. R.G. Pertwee Cannabinoid receptors and pain Prog Neurobiol 63 5 2001 569 611
14. R.G. Pertwee The pharmacology and therapeutic potential of cannabidiol V. DiMarzo Cannabinoids 2004 Kluwer Academic Publishers Dordrecht (Netherlands)
15. R. Mechoulam, L.A. Parker, and R. Gallily Cannabidiol: an overview of some pharmacological aspects J Clin Pharmacol 42 Suppl 11 2002 11S 19S
16. A.W. Zuardi, I. Shirakawa, E. Finkelfarb, and I.G. Karniol Action of cannabidiol on the anxiety and other effects produced by delta 9-THC in normal subjects Psychopharmacology 76 3 1982 245 250
17. A.W. Zuardi, S.L. Morais, F.S. Guimaraes, and R. Mechoulam Antipsychotic effect of cannabidiol [letter] J Clin Psychiat 56 10 1995 485 486
18. L.M. Bornheim, and M.P. Grillo Characterization of cytochrome P450 3A inactivation by cannabidiol: possible involvement of cannabidiol-hydroxyquinone as a P450 inactivator Chem Res Toxicol 11 10 1998 1209 1216
19. A.J. Hampson, M. Grimaldi, M. Lolic, D. Wink, R. Rosenthal, and J. Axelrod Neuroprotective antioxidants from marijuana Ann NY Acad Sci 899 2000 274 282
20. A.M. Malfait, R. Gallily, P.F. Sumariwalla, A.S. Malik, E. Andreakos, and R. Mechoulam The non-psychoactive cannabis constituent cannabidiol is an oral anti-arthritic therapeutic in murine collagen-induced arthritis Proc Natl Acad Sci USA 97 17 2000 9561 9566
21. T. Bisogno, L. Hanus, L. De Petrocellis, S. Tchilibon, D.E. Ponde, and I. Brandi Molecular targets for cannabidiol and its synthetic analogues: effect on vanilloid VR1 receptors and on the cellular uptake and enzymatic hydrolysis of anandamide Brit J Pharmacol 134 4 2001 845 852
22. I.G. Karniol, and E.A. Carlini Pharmacological interaction between cannabidiol and delta 9-tetrahydrocannabinol Psychopharmacologia 33 1 1973 53 70
23. P.J. Welburn, G.A. Starmer, G.B. Chesher, and D.M. Jackson Effect of cannabinoids on the abdominal constriction response in mice: within cannabinoid interactions Psychopharmacologia 46 1 1976 83 85
24. J.M. Monti Hypnoticlike effects of cannabidiol in the rat Psychopharmacology (Berl) 55 3 1977 263 265
25. R.E. Musty, and R. Sands Effects of marijuana extract distillate and cannabidiol on variable interval performance as a function of food deprivation Pharmacology 16 4 1978 199 205
26. A.W. Zuardi, and I.G. Karniol Effects on variable-interval performance in rats of delta 9- tetrahydrocannabinol and cannabidiol, separately and in combination Braz J Med Biol Res 16 2 1983 141 146
27. H. Rosenkrantz, and D.W. Hayden Acute and subacute inhalation toxicity of Turkish marihuana, cannabichromene, and cannabidiol in rats Toxicol Appl Pharmacol 48 3 1979 375 386
28. C.G. Stott, G.W. Guy, S. Wright, and B.A. Whittle The genotoxicology of Sativex Conference on the Cannabinoids, 2005 June 2005 International Cannabinoid Research Society Clearwater (FL)
29. A.W. Zuardi, E. Finkelfarb, O.F. Bueno, R.E. Musty, and I.G. Karniol Characteristics of the stimulus produced by the mixture of cannabidiol with delta 9-tetrahydrocannabinol Arch Int Pharmacodyn Ther 249 1 1981 137 146
30. P. Fadda, L. Robinson, W. Fratta, R.G. Pertwee, and G. Riedel Differential effects of THC- or CBD-rich cannabis extracts on working memory in rats Neuropharmacology 47 8 2004 1170 1179
31. L.E. Hollister Cannabidiol and cannabinol in man Experientia 29 7 1973 825 826
32. M. Perez-Reyes, M.C. Timmons, K.H. Davis, and E.M. Wall A comparison of the pharmacological activity in man of intravenously administered delta9-tetrahydrocannabinol, cannabinol, and cannabidiol Experientia 29 11 1973 1368 1369
33. I.G. Karniol, I. Shirakawa, N. Kasinski, A. Pfeferman, and E.A. Carlini Cannabidiol interferes with the effects of delta 9-tetrahydrocannabinol in man Eur J Pharmacol 28 1 1974 172 177
34. US Government Additional scientific data considered by the Drug Enforcement Administration in evaluating Jon Gettman's petition to initiate rulemaking proceedings to reschedule marijuana Federal Register Drug and chemical evaluation section OoDC, Drug Enforcement Administration 2001 US Government Printing Office Washington (DC) 20053 20071
35. M.A. ElSohly, S.A. Ross, Z. Mehmedic, R. Arafat, B. Yi, and B.F. Banahan 3rd Potency trends of delta9-THC and other cannabinoids in confiscated marijuana from 1980-1997 J Forensic Sci 45 1 2000 24 30
36. J. De Vry, K.R. Jentzsch, E. Kuhl, and G. Eckel Behavioral effects of cannabinoids show differential sensitivity to cannabinoid receptor blockade and tolerance development Behav Pharmacol 15 1 2004 1 12
37. L.E. Hollister, and H. Gillespie Interactions in man of delta-9-tetrahydrocannabinol. II. Cannabinol and cannabidiol Clin Pharmacol Ther 18 1 1975 80 83
38. W.S. Dalton, R. Martz, L. Lemberger, B.E. Rodda, and R.B. Forney Influence of cannabidiol on delta-9-tetrahydrocannabinol effects Clin Pharmacol Ther 19 3 1976 300 309
39. L. Lemberger, B. Dalton, R. Martz, B. Rodda, and R. Forney Clinical studies on the interaction of psychopharmacologic agents with marihuana Ann NY Acad Sci 281 1976 219 228
40. E.A. Carlini, and J.M. Cunha Hypnotic and antiepileptic effects of cannabidiol J Clin Pharmacol 21 Suppl. 8-9 1981 417S 427S
41. M.J. Wallace, R.E. Blair, K.W. Falenski, B.R. Martin, and R.J. DeLorenzo The endogenous cannabinoid system regulates seizure frequency and duration in a model of temporal lobe epilepsy J Pharmacol Exp Ther 307 1 2003 129 137
42. M.J. Wallace, B.R. Martin, and R.J. DeLorenzo Evidence for a physiological role of endocannabinoids in the modulation of seizure threshold and severity Eur J Pharmacol 452 3 2002 295 301
43. J. Killestein, E.L. Hoogervorst, M. Reif, N.F. Kalkers, A.C. Van Loenen, and P.G. Staats Safety, tolerability, and efficacy of orally administered cannabinoids in MS Neurology 58 9 2002 1404 1407
44. E.B. Russo Safety, tolerability and efficacy of orally administered cannabinoids in MS Neurology 60 4 2003 729 730
45. C. Vaney, M. Heinzel-Gutenbrunner, P. Jobin, F. Tschopp, B. Gattlen, and U. Hagen Efficacy, safety and tolerability of an orally administered cannabis extract in the treatment of spasticity in patients with multiple sclerosis: a randomized, double-blind, placebo-controlled, crossover study Mult Scler 10 2004 417 424
46. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, and A. Nunn Cannabinoids for treatment of spasticity and other symptoms related to multiple sclerosis (CAMS study): multicentre randomised placebo-controlled trial Lancet 362 9395 2003 1517 1526
47. P. Fox, P.G. Bain, S. Glickman, C. Carroll, and J. Zajicek The effect of cannabis on tremor in patients with multiple sclerosis Neurology 62 7 2004 1105 1109
48. J. Zajicek, P. Fox, H. Sanders, D. Wright, J. Vickery, and A. Nunn The cannabinoids in MS study - final results from 12 months follow-up Mult Scler 10 Suppl. 2004 S115
49. G. Pryce, and D. Baker Emerging properties of cannabinoid medicines in management of multiple sclerosis Trends Neurosci 28 5 2005 272 276
50. C.B. Carroll, P.G. Bain, L. Teare, X. Liu, C. Joint, and C. Wroath Cannabis for dyskinesia in Parkinson disease: a randomized double-blind crossover study Neurology 63 7 2004 1245 1250
51. K. Venderova, E. Ruzicka, V. Vorisek, and P. Visnovsky Survey on cannabis use in Parkinson's disease: subjective improvement of motor symptoms Movement Disord 19 9 2004 1102
52. E.B. Russo Introduction. Cannabis: from pariah to prescription J Cannabis Ther 3 3-4 2003 1 29
53. G.W. Guy, and M.E. Flint A single centre, placebo-controlled, four period, crossover, tolerability study assessing pharmacokinetic effects, pharmacokinetic characteristics and cognitive profiles of as single dose of three formulations of cannabis based medicine extracts (CBMEs) (GWPD9901), plus a two period tolerability study comparing pharmacodynamic effects and pharmacokinetic characteristics of a single dose of a cannabis based medicine extract given via two administration routes (GWPD9901 EXT) J Cannabis Ther 3 3 2003 35 77
54. G.W. Guy, and P. Robson A Phase I, double blind, three-way crossover study to assess the pharmacokinetic profile of cannabis based medicine extract (CBME) administered sublingually in variant cannabinoid ratios in normal healthy male volunteers (GWPK02125) J Cannabis Ther 3 4 2003 121 152
55. A.N. Nicholson, C. Turner, B.M. Stone, and P.J. Robson Effect of delta-9-tetrahydrocannabinol and cannabidiol on nocturnal sleep and early-morning behavior in young adults J Clin Psychopharmacol 24 3 2004 305 313
56. D.T. Wade, P. Robson, H. House, P. Makela, and J. Aram A preliminary controlled study to determine whether whole-plant cannabis extracts can improve intractable neurogenic symptoms Clin Rehabil 17 2003 18 26
57. W. Notcutt, M. Price, R. Miller, S. Newport, C. Phillips, and S. Simmonds Initial experiences with medicinal extracts of cannabis for chronic pain: results from 34 "N of 1" studies Anaesthesia 59 2004 440 452
58. C.M. Brady, R. DasGupta, C. Dalton, O.J. Wiseman, K.J. Berkley, and C.J. Fowler An open-label pilot study of cannabis based extracts for bladder dysfunction in advanced multiple sclerosis Mult Scler 10 2004 425 433
59. J.S. Berman, C. Symonds, and R. Birch Efficacy of two cannabis based medicinal extracts for relief of central neuropathic pain from brachial plexus avulsion: results of a randomised controlled trial Pain 112 3 2004 299 306
60. E.A. Carlini The good and the bad effects of (-)trans-delta-9- tetrahydrocannabinol (Delta(9)-THC) on humans Toxicon 44 4 2004 461 467
61. Collin C. A cannabis-based medicine (Sativex) has sustained efficacy in the treatment of spasticity in multiple sclerosis. In: Association of British Neurologists; Belfast, Northern Ireland; 2005 April 1.
62. D.J. Rog, T. Nurmiko, T. Friede, and C. Young Randomized controlled trial of cannabis based medicine in central neuropathic pain due to multiple sclerosis Neurology 65 6 2005 812 819
63. N. Attal, L. Brasseur, D. Guirimand, S. Clermond-Gnamien, S. Atlami, and D. Bouhassira Are oral cannabinoids safe and effective in refractory neuropathic pain? Eur J Pain 8 2 2004 173 177
64. S. Clermont-Gnamien, S. Atlani, N. Attal, F. Le Mercier, F. Guirimand, and L. Brasseur Utilisation thérapeutique du delta-9- tétrahydrocannabinol (dronabinol) dans les douleurs neuropathiques réfractaires [The therapeutic use of D9-tetrahydrocannabinol (dronabinol) in refractory neuropathic pain] Presse Med 31 39 Pt 1 2002 1840 1845
65. Z. Rudich, J. Stinson, M. Jeavons, and S.C. Brown Treatment of chronic intractable neuropathic pain with dronabinol: case report of two adolescents Pain Res Manag 8 4 2003 221 224
66. K.B. Svendsen, T.S. Jensen, and F.W. Bach Does the cannabinoid dronabinol reduce central pain in multiple sclerosis? Randomised double blind placebo controlled crossover trial Brit Med J 329 7460 2004 253
67. Nurmikko TJ, Serpell MG, Hoggart B, Toomey PJ, Morlion BJ. A multi-center, double-blind, randomized, placebo-controlled trial of oro-mucosal cannabis-based medicine in the treatment of neuropathic pain characterized by allodynia. In: American Academy of Neurology. Miami Beach (FL); 2005 April 14.
68. D.T. Wade, P. Makela, P. Robson, H. House, and C. Bateman Do cannabis-based medicinal extracts have general or specific effects on symptoms in multiple sclerosis? A double-blind, randomized, placebo-controlled study on 160 patients Mult Scler 10 4 2004 434 441
69. Robson P, Wade D, Makela P, House H, Bateman C. Cannabis-based medicinal extract (Sativex) produced significant improvements in a subjective measure of spasticity which were maintained on long-term treatment with no evidence of tolerance. In: International Association for Cannabis as Medicine; Leiden, Netherlands; 2005 September 9.
70. Johnson JR, Potts R. Cannabis-based medicines in the treatment of cancer pain: a randomised, double-blind, parallel group, placebo controlled, comparative study of the efficacy, safety and tolerability of Sativex and Tetranabinex in patients with cancer-related pain. In: British Pain Society. Edinburgh, Scotland; 2005 March 8-11.
71. Russo EB. Sativex cannabis based medicine maintains improvements in sleep quality in patients with multiple sclerosis and neuropathic pain. In: American Academy of Neurology. Miami Beach (FL); 2005 April 12.
72. E.B. Russo, G.W. Guy, P.J. Robson, and R.G. Pertwee Tolerance and THC: cannabis based medicine extracts maintain long-term clinical efficacy without dosage increases 2004 Symposium on the cannabinoids 2004 International Cannabinoid Research Society Paestum (Italy) 90
73. A.J. Hampson, M. Grimaldi, J. Axelrod, and D. Wink Cannabidiol and (-)Delta9-tetrahydrocannabinol are neuroprotective antioxidants Proc Natl Acad Sci USA 95 14 1998 8268 8273
74. C. Hamelink, A. Hampson, D.A. Wink, L.E. Eiden, and R.L. Eskay Comparison of cannabidiol, antioxidants and diuretics in reversing binge ethanol-induced neurotoxicity J Pharmacol Exp Ther 2005
75. K. Mishima, K. Hayakawa, K. Abe, T. Ikeda, N. Egashira, and K. Iwasaki Cannabidiol prevents cerebral infarction via a serotonergic 5- hydroxytryptamine1A receptor-dependent mechanism Stroke 36 5 2005 1077 1082
76. Russo EB, Burnett A, Hall B, Parker KK. Agonistic properties of cannabidiol at 5-HT-1a receptors. Neurochem Res 2005;30(8) [in press].
77. T. Iuvone, G. Esposito, R. Esposito, R. Santamaria, M. Di Rosa, and A.A. Izzo Neuroprotective effect of cannabidiol, a non-psychoactive component from Cannabis sativa, on beta-amyloid-induced toxicity in PC12 cells J Neurochem 89 1 2004 134 141
78. F.A. Moreira, and F.S. Guimaraes Cannabidiol inhibits the hyperlocomotion induced by psychotomimetic drugs in mice Eur J Pharmacol 512 2-3 2005 199 205
79. L. Volicer, M. Stelly, J. Morris, J. McLaughlin, and B.J. Volicer Effects of dronabinol on anorexia and disturbed behavior in patients with Alzheimer's disease Int J Geriatr Psychiat 12 9 1997 913 919
80. G.T. Carter, and B.S. Rosen Marijuana in the management of amyotrophic lateral sclerosis Am J Hosp Palliat Care 18 4 2001 264 270
81. C. Raman, S.D. McAllister, G. Rizvi, S.G. Patel, D.H. Moore, and M.E. Abood Amyotrophic lateral sclerosis: delayed disease progression in mice by treatment with a cannabinoid ALS and Other Motor Neuron Disorders 5 2004 33 39
82. Abood ME, Raman C, Kim K, Moore DH. Evaluation of cannabidiol in a mutant SOD1 mouse model of ALS. In: International alliance of ALS/MND associations. Philadelphia; 2004 December 3.
83. I. Lastres-Becker, F. Molina-Holgado, J.A. Ramos, R. Mechoulam, and J. Fernandez-Ruiz Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease Neurobiol Dis 19 1-2 2005 96 107
84. P. Consroe, and S.R. Snider Therapeutic potential of cannabinoids in neurological disorders R. Mechoulam Cannabinoids as therapeutic agents 1986 CRC Press Boca Raton (FL) 21 49
85. P. Consroe, J. Laguna, J. Allender, S. Snider, L. Stern, and R. Sandyk Controlled clinical trial of cannabidiol in Huntington's disease Pharmacol Biochem Behav 40 3 1991 701 708
86. D. Baker Therapeutic potential of cannabis and cannabinoids in experimental models of multiple sclerosis G.W. Guy B.A. Whittle P.J. Robson Medicinal uses of cannabis and cannabinoids 2004 Pharmaceutical Press London 141 164
87. A.N. Samaha, and T.E. Robinson Why does the rapid delivery of drugs to the brain promote addiction? Trends Pharmacol Sci 26 2 2005 82 87
88. E. Labigalini, L.R. Jr, and D.X. Rodrigues Therapeutic use of cannabis by crack addicts in Brazil J Psychoactive Drugs 31 4 1999 451 455
89. M. Dreher Crack heads and roots daughters: the therapeutic use of cannabis in Jamaica J Cannabis Ther 2 3-4 2002 121 133
90. D.L. Cichewicz, and S.P. Welch Modulation of oral morphine antinociceptive tolerance and naloxone-precipitated withdrawal signs by oral Delta 9-tetrahydrocannabinol J Pharmacol Exp Ther 305 3 2003 812 817
91. Y. Shavit, G. Wolf, I. Goshen, D. Livshits, and R. Yirmiya Interleukin-1 antagonizes morphine analgesia and underlies morphine tolerance Pain 115 1-2 2005 50 59
92. B. Watzl, P. Scuderi, and R.R. Watson Influence of marijuana components (THC and CBD) on human mononuclear cell cytokine secretion in vitro Adv Exp Med Biol 288 1991 63 70
93. M. Maccarrone, and A. Finazzi-Agro The endocannabinoid system, anandamide and the regulation of mammalian cell apoptosis Cell Death Differ 10 9 2003 946 955
94. M. Guzman, C. Sanchez, and I. Galve-Roperh Control of the cell survival/death decision by cannabinoids J Mol Med 78 11 2001 613 625
95. Vaccani A, Massi P, Parolaro D. Inhibition of human glioma cell growth by the non- psychoactive cannabidiol. In: First European workshop on cannabinoid research. Madrid; 2003 April 4-5. p. 66.
96. P. Massi, A. Vaccani, S. Ceruti, A. Colombo, M.P. Abbracchio, and D. Parolaro Antitumor effects of cannabidiol, a non-psychotropic cannabinoid, on human glioma cell lines J Pharmacol Exp Ther 308 3 2004 838 845
97. A. Vaccani, P. Massi, A. Colombo, T. Rubino, and D. Parolaro Cannabidiol inhibits human glioma cell migration through a cannabinoid receptor-independent mechanism Brit J Pharmacol 2005
98. L.A. Parker, R. Mechoulam, and C. Schlievert Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats Neuroreport 13 5 2002 567 570
99. S.R. Wachtel, M.A. ElSohly, R.A. Ross, J. Ambre, and H. de Wit Comparison of the subjective effects of delta9-tetrahydrocannabinol and marijuana in humans Psychopharmacology 161 2002 331 339
100. S.A. Varvel, D.T. Bridgen, Q. Tao, B. Thomas, B. Martin, and A. Lichtman {Delta}9-Tetrahydrocannabinol accounts for the antinociceptive, hypothermic, and cataleptic effects of marijuana in mice J Pharmacol Exp Ther 2005
101. B.A. Whittle, G.W. Guy, and P. Robson Prospects for new cannabis-based prescription medicines J Cannabis Ther 1 3-4 2001 183 205
102. Thomas A, Stevenson LA, Wease KN, Price MR, Baillie G, Ross RA, et al. Evidence that the plant cannabinoid delta-9-tetrahydrocannabivarin is a cannabinoid CB1 and CB2 antagonist. Brit J Pharmacol 2005 [in press].
103. R.G. Pertwee Advanced in cannabinoid receptor pharmacology in cannabis D.T. Brown Cannabis: The genus Cannabis 1998 Harwood Academic Publishers Amsterdam
104. V.M. Showalter, D.R. Compton, B.R. Martin, and M.E. Abood Evaluation of binding in a transfected cell line expressing a peripheral cannabinoid receptor (CB2): identification of cannabinoid receptor subtype selective ligands J Pharmacol Exp Ther 278 3 1996 989 999
105. C.G. Stott, G.W. Guy, S. Wright, and B.A. Whittle The effects of cannabis extracts Tetranabinex and Nabidiolex on human cyclo-oxygenase (COX) activity Symposium on the Cannabinoids, 2005 June 2005 International Cannabinoid Research Society Clearwater (FL)
106. G. Cabral Immune system F. Grotenhermen E.B. Russo Cannabis and cannabinoids: Pharmacology, toxicology and therapeutic potential 2001 Haworth Press Binghamton (NY) 279 287
107. E.B. Russo Handbook of psychotropic herbs: a scientific analysis of herbal remedies for psychiatric conditions 2001 Haworth Press Binghamton (NY)
108. A.W. Zuardi, and F.S. Guimaraes Cannabidiol as an anxiolytic and antipsychotic M.L. Mathre Cannabis in medical practice: a legal, historical and pharmacological overview of the therapeutic use of marijuana 1997 McFarland Jefferson (NC) 133 141
109. K.R. Müller-Vahl, U. Schneider, H. Prevedel, K. Theloe, H. Kolbe, and T. Daldrup Delta9-Tetrahydrocannabinol (THC) is effective in the treatment of tics in tourette syndrome: a 6-week randomized trial J Clin Psychiat 64 4 2003 459 465
110. E.B. Russo Clinical endocannabinoid deficiency (CECD): can this concept explain therapeutic benefits of cannabis in migraine, fibromyalgia, irritable bowel syndrome and other treatment-resistant conditions? Neuroendocrinol Lett 25 1-2 2004 31 39
111. L. Grinspoon, and J.B. Bakalar The use of cannabis as a mood stabilizer in bipolar disorder: anecdotal evidence and the need for clinical research J Psychoactive Drugs 30 2 1998 171 177
112. A.T. Weil, N.E. Zinberg, and J.M. Nelsen Clinical and psychological effects of marihuana in man Science 162 859 1968 1234 1242
113. S. Batkai, P. Pacher, D. Osei-Hyiaman, S. Radaeva, J. Liu, and J. Harvey-White Endocannabinoids acting at cannabinoid-1 receptors regulate cardiovascular function in hypertension Circulation 110 14 2004 1996 2002
114. C. Sanchez, I. Galve-Roperh, C. Canova, P. Brachet, and M. Guzman Delta9-tetrahydrocannabinol induces apoptosis in C6 glioma cells FEBS Lett 436 1 1998 6 10
115. P. Massi, A. Vaccani, S. Ceruti, A. Colombo, M.P. Abbracchio, and D. Parolaro Antitumor effects of cannabidiol, a nonpsychoactive cannabinoid, on human glioma cell lines J Pharmacol Exp Ther 308 3 2004 838 845
116. T. Jarvinen, D. Pate, and K. Laine Cannabinoids in the treatment of glaucoma Pharmacol Ther 95 2 2002 203 220
117. E.B. Russo, A. Merzouki, J. Molero Mesa, K.A. Frey, and P.J. Bach Cannabis improves night vision: a pilot study of dark adaptometry and scotopic sensitivity in kif smokers of the Rif Mountains of Northern Morocco J Ethnopharmacol 93 1 2004 99 104